Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$24.21M+26.2%-$34.57M-$30.09M-21.6%-$33.68M-124%-$32.79M-0.9%
$444K-35.1%$499K-29.2%$571K-27.5%$649K-24.0%$684K-28.0%
$7.11M+120%$6.07M+113%$3.86M+64.9%$3.24M+51.1%$3.23M+39.7%
-$39.11M-32.5%-$27.73M-$24.64M-$30.05M-121%-$29.52M-25.9%
$93K-68.9%$34K-94.4%$68K-34.0%$393K+146%$299K+7.2%
$6.28M+2,199%-$103.39M-16,989%-$66.88M-64,835%-$393K-146%-$299K-7.2%
$39.4M
$42.36M-66.7%$3.59M-94.9%$143.76M$612K+297%$127.38M+418%
$9.52M-90.2%-$127.53M-370%$52.23M-$29.83M-121%$97.56M+11,179%
-$39.21M-31.5%-$27.76M-$24.71M-$30.45M-121%-$29.82M-25.7%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Maze Therapeutics, Inc. Common Stock generate?
Maze Therapeutics, Inc. Common Stock (MAZE) generated -$121.5M in operating cash flow over the trailing twelve months.
What is Maze Therapeutics, Inc. Common Stock's free cash flow?
After $588.0K of capital expenditures, Maze Therapeutics, Inc. Common Stock's free cash flow was -$122.1M over the trailing twelve months.
Where does Maze Therapeutics, Inc. Common Stock's cash flow data come from?
Every line is extracted from Maze Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.